読み込み中
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
前日終値
$5.15
−$0.005 · -0.10%
日中の時刻はETです。市場データは遅延する場合があります。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日中レンジ
現在 $5.15
52週レンジ
現在 $5.15
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
25
割高
センチメント
54
まちまち
リスク
40
中程度のリスク
モメンタム
58
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日中レンジ
現在 $5.15
52週レンジ
現在 $5.15
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 3.51億 USD |
| 売上原価 | — | 8336.7万 USD | 7009万 USD | 6239万 USD | 1.67億 USD |
| 粗利益 | — | −8336.7万 USD | −7009万 USD | −6239万 USD | 1.84億 USD |
| 研究開発 | 1.48億 USD | 1.45億 USD | 1.33億 USD | 8883.6万 USD | 1.67億 USD |
| 販売・一般管理 | 3286.3万 USD | 4884.9万 USD | 4991.9万 USD | 4871.4万 USD | 4578.5万 USD |
| 営業費用 | 1.81億 USD | 1.1億 USD | 9407.2万 USD | 6826万 USD | 4578.5万 USD |
| 受取利息 | 1637.6万 USD | 2549万 USD | 2922.4万 USD | 1115.1万 USD | 21.3万 USD |
| 支払利息 | — | — | — | 1115.1万 USD | — |
| 減価償却費と償却費 | 41.6万 USD | 41.6万 USD | 41.6万 USD | 26万 USD | 2.9万 USD |
| 営業利益 | −1.81億 USD | −1.93億 USD | −1.64億 USD | −1.31億 USD | 1.38億 USD |
| 純利益 | −1.58億 USD | −1.68億 USD | −1.36億 USD | −1.16億 USD | 1.21億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$7.00
上昇余地（35.92%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1087.26万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM966.86万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF457.86万0.00%954億 USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS316.47万0.01%338.69億 USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB258.45万0.02%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO217.94万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA192.79万0.01%218.24億 USD0.03%$32.79+0.40%
U.S. Micro Cap Portfolio ETFDFMC121.04万0.02%75.58億 USD0.43%$57.813+0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAU.S. Micro Cap Portfolio ETFDFMCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
